Patent ID: 9439961
Filing Date: 2016-09-13
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method to suppress or reduce concomitantly occurring cerebral hemorrhage and cerebral infarction exacerbation that accompany the administration of a plasminogen activator after an acute stage of ischemic cerebral infarction in a human subject comprising administering to said subject a combination of a plasminogen activator and, a tyrosine kinase inhibitor that inhibits human VEGF-R2 response to VEGF, wherein administration of said combination extends the time window for administration of said plasminogen activator to said human subject after the onset of cerebral infarction beyond that for administration of said plasminogen activator alone, and wherein administration of said combination suppresses or reduces said concomitantly occurring cerebral hemorrhage and cerebral infarction exacerbation; and wherein the administration of said combination is between 3-6 hours of the onset of said cerebral infarction, and wherein the plasminogen activator and the inhibitor are administered in the same composition or administered separately; and within the tyrosine kinase inhibitor that inhibits human VEGF-R2 response to VEGF is selected from the group consisting of SU1498, SU5416, cediranib (AZD2171), sunitinib (SU11248), vatalanib (PTK787/ZK222584), sorafenib, and pazopanib (GW786034B).